Logotype for Cosciens Biopharma Inc

Cosciens Biopharma (CSCI) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Cosciens Biopharma Inc

Q3 2026 earnings summary

13 Nov, 2026

Executive summary

  • Q3 revenue rose 70% YoY to $2.516M, while consolidated net loss widened to $3.445M, primarily reflecting a $2.044M PGX impairment and acquisition-related costs.

  • Nualtis was acquired on September 10, adding oral thin-film development and manufacturing; 20 days of its results were included in Q3.

  • 9M net income was $7.113M, including $10.940M from discontinued operations; continuing operations recorded a $3.827M loss.

Financial highlights

  • Q3 revenue was $2.516M vs. $1.476M YoY; gross profit rose to $1.378M from $0.623M.

  • 9M revenue was $7.547M vs. $5.280M; gross profit was $3.909M vs. $1.745M.

  • Q3 consolidated net loss was $3.445M, or $3.45 per share, vs. $1.819M and $1.72 per share; $1.1M of acquisition and financing-related professional fees contributed to higher SG&A.

  • 9M consolidated net income was $7.113M vs. a $8.175M loss in 2025; discontinued operations contributed $10.940M of net income.

  • Cash and cash equivalents were $9.207M at September 30, 2026, vs. $7.307M at December 31, 2025.

Outlook and guidance

  • Management expects existing cash and projected operating cash flows to cover liabilities for at least 12 months, assuming debenture conversion; forecasts remain exposed to uncertain revenue and cash generation.

  • Liquidity forecasts assume required shareholder and TSX approvals, sufficient operating cash flows and timely payment of $6.0M deferred acquisition consideration; the debenture offering was expected to remain open through November 30, 2026.

  • Cost and cash-conservation measures include lower R&D spending and capex, operational restructuring, and manufacturing and procurement reviews to improve margins.

  • Development priorities include oat extraction improvements for avenanthramides and oat beta glucan, plus work on oat oil, protein and peptides; Rizatriptan OTF was expected to launch in Q4 2026.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Cosciens Biopharma